[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647948":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":46,"collaborators":25,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":25,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":25,"enrollmentInfo":58,"targetDuration":25,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":25,"overallStatus":67,"whyStopped":25,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1 : Reference Drug(AD-1161), Period 2 : Test Drug(AD-116A)",[13,14],"Drug: AD-116A","Drug: AD-1161",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B","Period 1 : Test Drug(AD-116A), Period 2 : Reference Drug(AD-1161)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-116A","Oral Capsule",[9,16],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"AD-1161",[9,16],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Soyoung Hwang","CONTACT","+82-31-891-6919","syhwang@addpharma.co.kr",[36],{"facility":37,"status":25,"city":38,"state":25,"zip":25,"country":39,"countryCode":25,"cosmosGeoPoint":40,"geoPoint":45,"contacts":25},"H PLUS YANGJI HOSPITAL, Seoul","Seoul","South Korea",{"type":41,"coordinates":42},"Point",[43,44],126.9784,37.566,{"lat":44,"lon":43},{"type":47,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100647948","phase-1-a-clinical-trial-to-evaluate-the-bioequivalence-of-ad-116a-compared-to-ad-1161-in-healthy-adult-male-volunteers-100647948",false,"NCT07715305","A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"MALE","19 Years",{"count":59,"type":60},44,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","The study compare and evaluate the bioequivalence between the administration of AD-116A and the administration of AD-1161 in healthy adult male volunteers",[66],"Benign Prostatic Hyperplasia","NOT_YET_RECRUITING","2026-07-15",{"date":70,"type":71},"2026-07-20","ACTUAL",{"date":73,"type":60},"2026-07",{"date":75,"type":60},"2026-08",{"name":5,"class":6},1]